It has been evidenced that liver cancer stem cells (LCSCs) are to blame hepatocellular carcinoma (HCC) occurrence, development, metastasis, and recurrence. Using iron-platinum nanoparticles (FePt-NPs) as a carrier and CD133 antigen as a target, a new strategy to targetly kill LCSCs by integrating HSV-TK suicide gene, ¹³¹I nuclide irradiation, and magnetic fluid hyperthermia (MFH) together was designed and investigated in the present study. The results showed that FePt-NPs modified with PEI (PEI-FePt-NPs) could bind with DNA, and the best binding ratio was 1 : 40 (mass ratio). Moreover, DNA binding to PEI-FePt-NPs could refrain from Dnase1 enzyme digestion and could release under certain conditions. LCSCs (CD133⁺ Huh-7 cells) were transfected with pHRE-Egr1-HSV-TK by PEI-FePt-NPs, and the transfection efficiency was %. These data showed a good potential of PEI-FePt-NPs as a gene transfer carrier.¹³¹I was labeled with anti-CD133McAb in order to facilitate therapy targeting. The combined intervention of pHRE-Egr1-HSV-TK/anti-CD133McAb-¹³¹I/MFH mediated by PEI-FePt-NPs could greatly inhibit LCSCs’ growth and induce cell apoptosis in vitro, significantly higher than any of the individual interventions (). This study offers a practicable idea for LCSC treatment, and PEI-FePt-NPs may act as novel nonviral gene vectors and a magnetic induction medium.

中文翻译：

---

FePt纳米粒子介导的pHRE-Egr1-HSV-TK / Anti-CD133McAb-131I / MFH联合治疗肝癌干细胞

已有证据表明，肝癌干细胞（LCSC）归咎于肝细胞癌（HCC）的发生，发展，转移和复发。以铁铂纳米颗粒（FePt-NPs）为载体，以CD133抗原为靶标，设计了一种新的策略，通过整合HSV-TK自杀基因，¹³¹ I核素辐射和磁流体热疗（MFH）来杀死LCSC。并在本研究中进行了调查。结果表明，PEI修饰的FePt-NP（PEI-FePt-NPs）可以与DNA结合，最佳结合比例为1:40（质量比）。而且，与PEI-FePt-NPs结合的DNA可以抑制Dnase1酶的消化，并在一定条件下可以释放。LCSC（CD133 ⁺ 通过PEI-FePt-NPs用pHRE-Egr1-HSV-TK转染Huh-7细胞，转染效率为 ％。这些数据表明，PEI-FePt-NPs作为基因转移载体的潜力很大。¹³¹ I用抗CD133McAb标记，以促进靶向治疗。PEI-FePt-NPs介导的pHRE-Egr1-HSV-TK / anti-CD133McAb- ¹³¹ I / MFH的联合干预可在体外显着抑制LCSCs的生长并诱导细胞凋亡，明显高于任何单独的干预措施（）。这项研究为LCSC治疗提供了一个可行的想法，而PEI-FePt-NPs可以作为新型非病毒基因载体和磁感应介质。